Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...